In the univariate analysis, the cumulative incidence of grades II–IV acute GVHD was significantly higher in patients receiving G‐CSF compared to those not receiving it, regardless of graft type (p = .005 for BMT, p = .055 for PBSCT, p = .021 for CBT) (Figure 1A–C). This evidence concerns the gene CSF3 and acute graft versus host disease.